CFTR and metabolic syndrome: This is especially relevant for CF patients with CFTR-related disorders and CF-related metabolic syndrome/CF-screen-positive inconclusive diagnosis patients carrying two rare mutations and of variable clinical consequences or of unknown functional significance who are unlikely to enter clinical trials.